Thermo Fisher ScientificTMO
TMO
About: Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).
Employees: 122,000
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 11 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
12% more first-time investments, than exits
New positions opened: 168 | Existing positions closed: 150
5% more capital invested
Capital invested by funds: $194B [Q2] → $204B (+$10.4B) [Q3]
3% more funds holding in top 10
Funds holding in top 10: 111 [Q2] → 114 (+3) [Q3]
3% more repeat investments, than reductions
Existing positions increased: 1,008 | Existing positions reduced: 976
1% more funds holding
Funds holding: 2,497 [Q2] → 2,515 (+18) [Q3]
4.95% less ownership
Funds ownership: 91.95% [Q2] → 87.0% (-4.95%) [Q3]
13% less call options, than puts
Call options by funds: $1.59B | Put options by funds: $1.82B
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$605
15%
upside
Avg. target
$649
24%
upside
High target
$718
37%
upside
11 analyst ratings
8 positive
73%
3 neutral
27%
0 negative
0%
Scotiabank Sung Ji Nam 50% 1-year accuracy 10 / 20 met price target | 15%upside $605 | Sector Perform Initiated | 23 Dec 2024 |
B of A Securities Derik De Bruin 26% 1-year accuracy 5 / 19 met price target | 26%upside $660 | Buy Maintained | 13 Dec 2024 |
Bernstein Eve Burstein 67% 1-year accuracy 4 / 6 met price target | 18%upside $620 | Market Perform Maintained | 24 Oct 2024 |
RBC Capital Conor McNamara 23% 1-year accuracy 9 / 39 met price target | 37%upside $718 | Outperform Maintained | 24 Oct 2024 |
Stifel Daniel Arias 17% 1-year accuracy 3 / 18 met price target | 27%upside $665 | Buy Maintained | 24 Oct 2024 |
Financial journalist opinion
Based on 11 articles about TMO published over the past 30 days
Neutral
Business Wire
1 week ago
Knipper Health Announces Transfer of Commercial Sample Management Business from Thermo Fisher Scientific
LAKEWOOD, N.J.--(BUSINESS WIRE)--Knipper Health, Inc., the largest supplier of end-to-end pharmaceutical healthcare marketing services and solutions in the U.S. serving the biopharmaceutical and medical industries, announced today the Company has been assigned the assets of Patheon Pharma Services sample and fulfillment services, from Thermo Fisher Scientific, located in Memphis TN. Included in the assignment, Knipper will retain all colleagues, as well as the Memphis site, along with all custo.
Negative
Zacks Investment Research
1 week ago
Bioproduction Prospects to Drive TMO Shares Despite Macroeconomic Woes
TMO's recent strategic acquisitions, including the $3.1-billion acquisition of Olink Holdings, are likely to drive future growth.
Positive
Seeking Alpha
1 week ago
Thermo Fisher: The Cycle Has Already Turned Around
Thermo Fisher's stock is now a "buy" due to signs of recovery, including positive sales growth and stabilized margins, despite recent bearish trends. The company's post-pandemic challenges are easing, with optimistic executive comments and improved guidance for 2024, indicating a potential return to organic growth. Potential deregulation under Trump's administration could benefit Thermo Fisher by increasing demand for its equipment and consumables in a more competitive pharmaceutical market.
Negative
Zacks Investment Research
2 weeks ago
TMO Institutional & Insider Stock Sell-Offs Upset Market: How to Play
Investors are also concerned about Thermo Fisher's continuous decline in testing revenues due to the decline in COVID testing-related demand.
Positive
Zacks Investment Research
2 weeks ago
Should You Continue to Hold TMO Stock in Your Portfolio?
Investors continue to be optimistic about Thermo Fisher due to its strategic acquisitions and string of product launches.
Positive
Seeking Alpha
2 weeks ago
Thermo Fisher Scientific: Renewed Growth Momentum After The Pandemic
Thermo Fisher Scientific is well-positioned for growth due to its consistent revenue streams, strong M&A track record and minimal macroeconomic dependence. Despite a COVID-related revenue surge and subsequent correction, the company's valuation multiples are now reasonable, offering potential for capital appreciation. 2025 growth drivers include improved biotech funding and China's government stimulus.
Positive
Zacks Investment Research
3 weeks ago
TMO Stock to Gain From the New Additions to CTS Portfolio of Products
Thermo Fisher launches CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8 to enhance cell therapy development and production.
Neutral
Seeking Alpha
3 weeks ago
Thermo Fisher: M&A And Innovation To Drive Sales Growth
The reduction in revenues due to the decline in COVID-19-related products and services is expected to diminish or disappear in 2025. Thermo Fisher has been growing by acquiring other companies. This strategy led to the company growing 174% between 2017 and 2024 Q3 TTM. The company is filling more patents. In the first 11 months of 2024, Thermo Fisher had 254 published patents; its maximum number in a year.
Neutral
Business Wire
3 weeks ago
Thermo Fisher Scientific Launches CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8 to Enhance Cell Therapy Development and Production
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled the Gibco™ CTS™ Detachable Dynabeads™ CD4 and CTS Detachable Dynabeads CD8 (CTS Detachable Dynabeads)*. These latest products expand on Thermo Fisher's CTS Detachable Dynabeads platform, which represents a new generation of cell therapy isolation and/or activation products that prioritize cell quality while also creating greater workflow control. Ultimately, these products can hel.
Neutral
Business Wire
3 weeks ago
Thermo Fisher Scientific Completes $1B Share Repurchase
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the repurchase of $1 billion (1.9 million shares) of its common stock. As of December 3, 2024, $3 billion remained available under the company's share repurchase authorization. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to en.
Charts implemented using Lightweight Charts™